Cypress Wealth Services LLC Buys 269 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by on Mar 29th, 2023

Cypress Wealth Services LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 9,551 shares of the company’s stock after acquiring an additional 269 shares during the period. Cypress Wealth Services LLC’s holdings in Johnson & Johnson were worth $1,687,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Glassy Mountain Advisors Inc. bought a new stake in Johnson & Johnson in the fourth quarter worth $35,000. Retirement Financial Solutions LLC bought a new stake in Johnson & Johnson in the fourth quarter worth $40,000. TD Capital Management LLC bought a new stake in Johnson & Johnson in the third quarter worth $48,000. Piershale Financial Group Inc. bought a new stake in Johnson & Johnson in the fourth quarter worth $61,000. Finally, Cowa LLC purchased a new position in shares of Johnson & Johnson in the third quarter valued at about $58,000. 67.94% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ opened at $151.82 on Wednesday. The stock has a market cap of $395.38 billion, a PE ratio of 22.53, a price-to-earnings-growth ratio of 2.63 and a beta of 0.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $186.69. The firm’s 50-day simple moving average is $158.94 and its two-hundred day simple moving average is $167.39.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. The business had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business’s revenue was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.13 earnings per share. Analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were paid a $1.13 dividend. The ex-dividend date was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.98%. Johnson & Johnson’s dividend payout ratio is presently 67.06%.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on JNJ. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 25th. Citigroup boosted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. UBS Group began coverage on shares of Johnson & Johnson in a research report on Tuesday. They issued a “neutral” rating on the stock. Finally, Piper Sandler reduced their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $174.73.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.